Moderna is currently locked in a bureaucratic dance with the FDA, and the media is treating it like a technicality. They’re arguing over "immunogenicity data" and whether a few antibodies here or there justify a fast-track approval for their new mRNA flu vaccine.
They are asking the wrong question.
The industry is obsessed with whether mRNA can match the performance of traditional egg-based or cell-based flu shots. We are watching a pharmaceutical giant spend billions to reach parity with a product that is already mediocre. The "public dispute" between Moderna and the FDA isn't about safety or even efficacy in the way you think—it’s about the desperate need to justify an expensive platform that hasn't yet proven it can solve the influenza problem any better than a chicken egg from 1945.
The Antibody Trap
The central argument for Moderna’s mRNA-1010 is that it triggers a higher "titer" of antibodies against certain strains of the flu. This sounds great in a press release. It looks even better on a slide deck for investors.
But titers are a proxy, not a proof.
We have known for decades that the correlation between antibody levels and actual protection from the flu is, at best, inconsistent. Influenza is a shape-shifter. By the time the mRNA sequence is finalized, manufactured, and distributed, the virus has likely already drifted.
The "lazy consensus" says that mRNA is faster, so we can wait longer to see which strains are dominant before we start production. In theory, this closes the "mismatch window." In practice, we are still guessing. Having a faster printing press doesn't matter if you're still printing the wrong book.
I have watched biotech firms burn through venture capital chasing "faster" when they should have been chasing "different." If we are still targeting the hemagglutinin (HA) head—the part of the virus that mutates the fastest—it doesn't matter if the delivery vehicle is a lipid nanoparticle or a fertilized egg. You are still playing a game of Whac-A-Mole where the mole is faster than your arm.
The Manufacturing Myth
Moderna wants you to believe that the shift to mRNA is a logistical triumph. They claim it removes the "egg-adapted mutations" that often plague traditional vaccines.
Here is the truth: Egg-adaptation is a real issue, but it’s a minor one compared to the systemic failure of the "annual shot" model.
The FDA’s hesitation isn't just red tape. It’s a quiet acknowledgement that the bar for a new flu vaccine should be significantly higher than "not worse than the old one." If we are going to transition the entire global infrastructure to mRNA, the payoff should be a universal flu vaccine—one that targets the stable, conserved stalk of the virus.
Instead, Moderna is giving us a premium-priced version of the status quo.
The Cost of Convenience
Let’s talk about the business of "non-inferiority." In clinical trials, if your drug is "non-inferior," it means it isn't noticeably worse than the current standard.
Moderna is fighting for a world where "non-inferior" is the goal.
Why? Because mRNA is expensive to produce and even more expensive to store. The cold-chain requirements for mRNA products are a nightmare for rural clinics and developing nations. If the benefit is only a 5% or 10% bump in antibody titers—which may or may not translate to fewer hospitalizations—the math doesn't check out.
We are being sold a luxury upgrade for a car that still has a broken engine.
The Real Winner is Inertia
The FDA dispute is a distraction from the fact that we are ignoring superior technologies. Recombinant protein vaccines, like those from Sanofi or Novavax, already offer high-dose options that don't require the radical cellular hijacking of mRNA.
But mRNA has the momentum of the COVID-19 era. It has the "cool factor."
If you look at the data from Moderna’s own trials, the side effect profile—the "reactogenicity"—is consistently higher than traditional shots. People feel like they’ve been hit by a truck for 24 hours. If we ask the public to trade a day of fever and muscle aches for a flu shot that is only marginally better than the one they used to get, we are going to see a massive drop in compliance.
The public’s trust is a finite resource. Moderna is spending it on a product that offers a technical solution to a biological problem it hasn't actually solved.
The Question You Should Be Asking
When you see headlines about Moderna "resolving" its issues with the FDA, don't ask when the shot will be available.
Ask why we are settling for a technology that requires an annual update.
The true disruption in the flu space won't come from a faster way to code the same failing antigens. It will come from someone who stops looking at the flu as an annual subscription model and starts looking at it as a preventable disease.
Stop cheering for the "speed" of mRNA. Speed is irrelevant if you're headed toward a dead end.
Demand a vaccine that lasts five years, not five months. Demand a vaccine that targets the parts of the virus that can't change. Until then, we’re just watching two giants argue over who gets to sell us the same old failure in a shiny new package.
Vaccinate your portfolio if you must, but don't pretend this is a revolution in public health. It's just a better way to bill the insurance companies.
